Browse the corpus

Fabry disease is a rare, X-linked lysosomal storage disorder caused by deficient activity of the enzyme alpha-galactosidase A, resulting in progressive accumulation of globotriaosylceramide in various organs. This course reviews this multisystemic condition that primarily affects hemizygous males, including the clinical manifestations in childhood with acroparesthesia, angiokeratoma, hypohidrosis, corneal and lenticular abnormalities, and renal dysfunction progressing to end-stage renal disease. Cardiac involvement, cerebrovascular events, and neurological manifestations, which often emerge in adulthood, are also discussed. This activity also explores Fabry disease’s pathophysiology, diagnostic approaches, which rely on detecting low alpha-galactosidase A activity or identifying pathogenic mutations, and management strategies. Participants will gain enhanced skills in recognizing early signs, interpreting laboratory and imaging results, and coordinating interprofessional care, including genetic counseling, early initiation of enzyme replacement therapy, which remains essential to slow disease progression, preserve organ function, and improve quality of life, and renal and cardiovascular monitoring. This activity for healthcare professionals is designed to enhance the learner's competence in identifying Fabry disease, performing the recommended evaluation, and implementing an appropriate interprofessional approach to managing this condition, thereby optimizing therapeutic decision-making and improving long-term outcomes for individuals affected by this condition. Objectives: Identify characteristic clinical manifestations of Fabry disease across different organ systems. Apply evidence-based diagnostic approaches, including enzyme assays and genetic testing, to confirm Fabry disease. Determine individualized management plans for Fabry disease, including enzyme replacement therapy to slow disease progression. Coordinate interprofessional management strategies to optimize team communication and outcomes in patients with Fabry disease. Access free multiple choice questions on this topic.

Fabry disease represents an X-linked, multisystem lysosomal storage disorder caused by defective function of the enzyme alpha-galactosidase A (α-Gal A). Enzyme deficiency results in progressive lysosomal accumulation of globotriaosylceramide and related glycosphingolipids within cells throughout the body. The disorder follows an X-linked inheritance pattern and primarily affects hemizygous males. Disease onset typically occurs in childhood in male patients, triggering a cascade of cellular events that leads to characteristic clinical manifestations. Common presenting features include severe episodic pain in the extremities consistent with acroparesthesia, microvascular skin lesions, eg, angiokeratomas, and abnormalities of sweating that may manifest as anhidrosis, hypohidrosis, or hyperhidrosis. Ocular involvement includes corneal and lenticular abnormalities, while progressive renal involvement leads to proteinuria and eventual end-stage renal disease. Young males presenting with cerebrovascular events in combination with myocardial infarction and renal dysfunction warrant strong clinical consideration for Fabry disease.[1]

Researchers have identified hundreds of mutations in the gene encoding α-Gal A on the X chromosome that cause Fabry disease. Reduced or absent enzyme activity drives lysosomal accumulation of glycosphingolipids, primarily cerebroside trihexosides, within multiple tissues. Progressive glycolipid deposition promotes endothelial cell swelling and proliferation, ultimately resulting in renal failure during the third to fourth decade of life, along with cardiac disease, cerebrovascular events, and premature death. Mutations producing the classic Fabry phenotype lead to widespread multisystem involvement. In contrast, milder variants associated with missense mutations demonstrate a more limited presentation, with disease manifestations largely confined to cardiac abnormalities.[2]

Prevalence in white male populations has been reported to range from approximately 1:17,000 to 1:117,000 for Fabry disease. Classic Fabry disease mutations are seen in approximately 1:22,000 to 1:40,000 males, and atypical presentations are associated with about 1:1000 to 1:3000 males and 1:6000 to 1:40,000 females. According to targeted screening programs, evaluating patients on dialysis and newborn screening for enzyme activity suggests that atypical later-onset Fabry disease predominantly affects the cardiovascular, cerebrovascular, or renal systems. Newborn screening in northern Italy had an incidence of 1:7,879 newborns; all individuals had the later-onset or an unclassified variant of Fabry disease. The incidence in Washington State and Illinois was similar at 1:6,000 to 1:9,000 individuals, whereas the incidence in Missouri was 1:2,913 to 1:3,277 individuals. The incidence in Hungary, Austria, and Spain was 1:3,000 to 1:4,000 individuals

The precise mechanisms underlying the pathogenesis of Fabry disease remain incompletely defined. Fabry disease belongs to the group of X-linked inherited lysosomal storage disorders characterized by α-Gal A deficiency, which leads to lysosomal accumulation of globotriaosylceramide (Gb3). Fibrosis, inflammation, and oxidative stress contribute significantly to the disease process. Accumulation of lysosomal Gb3 promotes nitric oxide release, a factor implicated in the development of vasculopathy. Glycosphingolipid deposition within other tissues, including macrophages and lymphocytes, contributes to inflammatory responses, oxidative injury, and progressive tissue damage. Organs most frequently affected include the skin, heart, kidneys, and brain. In the kidneys, Gb3 accumulates predominantly in the glomeruli, followed by deposits in the distal tubules. This distribution correlates with the early development of proteinuria and polyuria. The mechanisms underlying renal sinus cyst formation in Fabry disease remain poorly understood.[3]

Various biopsies may be performed to evaluate patients for Fabry disease histologically. Skin biopsy typically demonstrates increased lipid content within affected tissues. Lipid deposits may also appear within muscle fibers, endothelial cells, and ganglion cells.[4] Histologic examination commonly reveals small-vessel angiomas resulting from cumulative vascular cell injury within the dermis, accompanied by vessel dilation. Renal biopsy demonstrates globotriaosylceramide accumulation within podocytes, highlighted by special staining techniques and most clearly visualized on electron microscopy, where characteristic intracellular inclusions become apparent.[5] Endomyocardial biopsy allows identification of characteristic globotriaosylceramide inclusions within cardiac tissue. Detection of these inclusions can establish the diagnosis in patients presenting with left ventricular hypertrophy or heart failure.

Clinical assessment is an essential component of the evaluation of Fabry's disease. A thorough medical history can reveal clinical features associated with this condition, including high blood pressure with renal dysfunction. Clinical history should be taken with specific attention to heat intolerance, abnormal decreases in sweat and tear production, and cerebrovascular accident. Clinicians should consider genetic counseling in particular, given the X-linked pattern of inheritance. Affected males often develop Fabry disease during childhood or early adolescence, with potential involvement of any organ system. Clinical presentation commonly includes painful acroparesthesias, hypohidrosis, and gastrointestinal symptoms, eg, abdominal cramping and diarrhea. Cutaneous manifestations consist of microvascular lesions that may appear as small petechiae around the umbilicus. Ocular involvement includes lenticular opacities and corneal dystrophy. Disease progression varies among individuals but frequently includes polyuria, polydipsia, and proteinuria, advancing to end-stage renal disease, cardiac conduction abnormalities, valvular defects, cerebrovascular accidents, and other neurological manifestations during the third to fourth decade of life. Additional complaints may include lymphadenopathy and difficulty tolerating heat or cold exposure, as well as reduced tolerance for strenuous exercise.

Clinicians should maintain a high index of suspicion for Fabry disease in individuals presenting with the previously described signs and symptoms, supported by findings from a comprehensive personal and family history and detailed physical examination. Initial evaluation benefits from a basic metabolic panel assessing electrolyte balance and renal function, urine sediment analysis for oval fat bodies, electrocardiography, and echocardiography to identify conduction or structural abnormalities. Radiologic studies, including chest x-ray, computed tomography (CT), CT angiography, magnetic resonance imaging (MRI), magnetic resonance angiography (MRA), and MR spectroscopy, may support evaluation of neurological involvement. Definitive diagnosis requires demonstration of reduced α-Gal A activity in leukocytes or plasma. When enzyme assays or genetic testing are unavailable, a skin or kidney biopsy may establish the diagnosis by identifying characteristic glycolipid deposits. Electron microscopy of renal biopsy specimens reveals concentric lamellar inclusions, commonly referred to as myeloid or zebra bodies.[6]

Fabry disease is completely incurable. The patient needs supportive treatment by replacing the deficient enzyme α-Gal A (alpha or beta) as soon as the diagnosis is made, regardless of the presence or absence of clinical manifestations in affected males and patients on renal replacement therapy. Female carriers and affected males with decreased α-Gal A levels should receive enzyme replacement only in the presence of kidney, heart, or neurological features. Patients on long-term dialysis should also receive enzyme replacement therapy. Hypertension in these patients should be managed with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.[7] Either enzyme alpha or enzyme beta replacement infusions should be given every 2 weeks, based on body weight calculations. Precautions should be taken considering infusion-related reactions. Slow infusion over 1 to 2 hours, along with prior administration of antipyretics, should be considered.[7] Additionally, patients with Fabry disease and end-stage renal disease can be safely considered for renal transplantation with the continued enzyme replacement posttransplant.

Following the occurrence of a first stroke, affected individuals face a heightened risk of recurrent cerebrovascular events. Heterozygous females typically have a milder clinical course than males, with fewer and less severe manifestations of the disease.

Management of Fabry disease benefits from the involvement of a neurologist with expertise in stroke and Fabry disease to evaluate and manage cerebrovascular complications. Furthermore, care coordination should include a cardiologist when an embolic stroke occurs to assess cardiac sources and guide appropriate therapy. A nephrologist plays a central role in the management of kidney failure and progressive renal involvement. Evaluation and treatment of cutaneous manifestations require consultation with a dermatologist experienced in the management of Fabry-related skin lesions.

Deterrence and patient education in Fabry disease focus on early recognition, genetic counseling, and adherence to lifelong management strategies to reduce complications and improve quality of life. Clinicians should educate patients and families about the X-linked inheritance pattern, emphasizing the importance of screening at-risk relatives for early diagnosis and intervention. Teaching patients to recognize initial symptoms, eg, acroparesthesia, hypohidrosis, angiokeratomas, and changes in renal or cardiac function, can promote timely medical evaluation. Education should also include information on the benefits and expectations of enzyme replacement therapy, strategies to manage infusion-related reactions, and the necessity of consistent follow-up with interprofessional teams. Empowering patients with knowledge about lifestyle modifications, symptom monitoring, and adherence to therapy enhances self-management, prevents disease progression, and supports long-term outcomes.[8]

Patients with Fabry disease need to be managed in an interprofessional team approach, with input and regular follow-up from physicians in neurology and ophthalmology, in addition to experts in managing diseases of the kidney, heart, and skin. Every year, patients should be screened for new-onset symptoms with close monitoring of complete blood count and renal function panel, along with a workup for proteinuria. Cardiology monitoring, including imaging and electrophysiological studies, should be performed within 1 to 2 years. Screening for family members includes an enzymatic assay for deficient α-Gal A activity in both symptomatic male and female relatives. Currently, no evidence supports routine prenatal screening and enzyme replacement in infants.

Fabry disease is a rare X-linked lysosomal storage disorder characterized by excessive lipid deposition in tissues due to deficient alpha-galactosidase A activity. The condition primarily affects males and can manifest in childhood or early adulthood with stroke, cardiac complications, angiokeratomas, painful neuropathies, or progressive renal failure. Early diagnosis significantly improves outcomes, allowing timely initiation of enzyme replacement therapy and supportive management. When the disorder is identified during pregnancy, genetic and prenatal counseling are essential for family planning and risk assessment. Effective management of Fabry disease requires interprofessional collaboration to optimize patient-centered care. Physicians, advanced practitioners, and nurses share responsibility for early detection, coordination of enzyme replacement therapy, and continuous patient education on disease progression and lifestyle modifications. Pharmacists play a crucial role in selecting and monitoring antiplatelet or anticoagulant therapy for stroke prevention and managing pain through appropriate anticonvulsant use. Physical and occupational therapists support functional independence and quality of life, while transplant teams evaluate candidates for renal replacement. Through coordinated communication, shared decision-making, and comprehensive follow-up, healthcare teams can improve safety, adherence, and long-term outcomes for patients living with Fabry disease.[9]